RT Journal Article
SR Electronic
T1 COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20085928
DO 10.1101/2020.04.30.20085928
A1 Vuagnat, Perrine
A1 Frelaut, Maxime
A1 Ramtohul, Toulsie
A1 Basse, Clémence
A1 Diakite, Sarah
A1 Noret, Aurélien
A1 Bellesoeur, Audrey
A1 Servois, Vincent
A1 Hequet, Delphine
A1 Laas, Enora
A1 Kirova, Youlia
A1 Cabel, Luc
A1 Pierga, Jean-Yves
A1 ,
A1 Bozec, Laurence
A1 Paoletti, Xavier
A1 Cottu, Paul
A1 Bidard, François-Clément
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.04.30.20085928.abstract
AB Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France).Methods An IRB-approved prospective registry was set up at ICH on March 13th, 2020 for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features and outcome. Data extraction was done on April 25th, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT-scan abnormalities.Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N=41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (>70) were the two factors associated with a higher risk of intensive care unit admission and/or death.Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInstitut Curie, Université de Versailles Saint Quentin and Université Paris-Saclay (no grant number applicable).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during this study are not publicly available due to French HIPAA (birthdate, admission date, discharge date, date of death), but are available from the corresponding author on reasonable request.